title: [Loco-regional fibrinolysis in the treatment of acute, non-traumatic ischemia of an artery. Use of PTFE, homologous vein, and Dacron in the treatment of acute thrombosis].
abstract: The acute thrombosis of a bypass graft can always be a common and challenging problem for the vascular surgeon, since surgical revascularization procedures can often result in failure, limb loss and infection. Since over the past 15 years literature reports emphasize the efficacy of intraarterial thrombolytic therapy (IATT) in achieving clot lysis and initial patency of thrombosed arteries and grafts, the purpose of this study is to verify if IATT with urokinase represents a valid alternative procedure to surgery. From our experience of 18 cases of lower limb ischemia, 9 of which graft thrombosis and 9 native artery occlusions, 3 cases of acute thrombosis of lower extremity bypass grafts, successfully treated with IATT are considered. After arteriography proof of lower extremity artery or bypass graft occlusion, thrombolytic therapy with urokinase was delivered at a rate of 100,000 UI/hour for 24/48 hours. At the conclusion of the thrombolytic treatment, percutaneous transluminal angioplasty (PTA) was performed on any residual stenosis of the bypass graft. In all three cases complete clot lysis within 48 hours was obtained, with patency of the bypass graft at two years follow-up. Urokinase in our experience, has always given good results. In many cases restoration of normal blood flow was obtained in bypass grafts thrombosed a three days. Urokinase has also been helpful in defining the causes of the occlusion (stenosis proximal or distal to the bypass) or of the anastomosis itself. Regional urokinase thrombolytic therapy, even if expensive, represents a primary tool for the vascular surgeon, since excellent results may be obtained, especially in cases where surgery is of high risk.
authors.affiliation: Divisione Chirurgia Generale, Ospedale CTO, ASI RM C, Roma.
authors.forename: M
authors.initials: M
authors.lastname: Palombi
authors.forename: S
authors.initials: S
authors.lastname: Sposato
authors.forename: A
authors.initials: A
authors.lastname: Stefanuto
authors.forename: O
authors.initials: O
authors.lastname: Bochicchio
authors.forename: M
authors.initials: M
authors.lastname: Gargiulo
authors.forename: F
authors.initials: F
authors.lastname: Berardi
authors.forename: G
authors.initials: G
authors.lastname: D'Elia
mesh_terms: D000208:Acute Disease; D000368:Aged; D005260:Female; D006801:Humans; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000627:therapeutic use*; D011093:Polyethylene Terephthalates; D011138:Polytetrafluoroethylene; D012189:Retrospective Studies; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000188:drug therapy* / Q000601:surgery; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*; D014656:Vascular Surgical Procedures / Q000379:methods*; D014680:Veins / Q000637:transplantation*
chemical_list: D011093:Polyethylene Terephthalates; D011138:Polytetrafluoroethylene; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator